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Objectives. This study investigated the incidence, predisposing
factors and significance of the onset of atrial fibrillation (AF) in
patients with chronic congestive heart failure (CHF).
Background. The association between CHF and AF is well
documented, but the factors that predispose to the onset of the
arrhythmia and its impact remain controversial.
Methods. We prospectively followed up 344 patients with CHF
and sinus rhythm (SR). Over a period of 19 6 12 months (mean 6
SD), 28 patients developed atrial fibrillation (AF), which became
chronic in 18.
Results. At baseline, no differences were found in any clinical
and hemodynamic variables between patients who developed
chronic AF and those who did not. Reversible AF occurring during
follow-up and lower mitral flow velocity at atrial contraction as
detected at the last evaluation in SR were independent predictors
of the subsequent development of chronic AF. When AF occurred,
New York Heart Association functional class worsened (from
2.4 6 0.5 to 2.9 6 0.6, p 5 0.0001), peak exercise oxygen
consumption declined (from 16 6 5 to 11 6 5 ml/kg per min, p 5
0.002), cardiac index decreased (from 2.2 6 0.4 to 1.8 6 0.4, p 5
0.0008), and mitral and tricuspid regurgitation increased (from
grade 1.8 6 1.1 to grade 2.4 6 1.4, p 5 0.0001 and from grade
1.0 6 1.2 to grade 1.8 6 1.2, p 5 0.001, respectively). Systemic
thromboembolism occurred in 3 of the 18 patients with AF. Nine
of 18 patients died after AF, and the occurrence of AF was a
predictor of major cardiac events.
Conclusions. In patients with CHF, reversible AF and reduction
of left atrial contribution to left ventricular filling predict the
subsequent development of chronic AF. The onset of AF is
associated with clinical and hemodynamic deterioration and may
predispose to systemic thromboembolism and poorer prognosis.
(J Am Coll Cardiol 1998;32:197–204)
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Structural cardiac diseases underlie atrial fibrillation (AF) in
80% to 97% of patients, and chronic congestive heart failure
(CHF) is one of its most frequent precursors (1,2). Whereas
the association between CHF and AF is well documented, the
factors that predispose to the onset of this arrhythmia are not.
In addition, the clinical and hemodynamic impact of AF in
patients with CHF remains controversial. Some studies (3–6)
have shown that such patients have more compromized hemo-
dynamic function, lower exercise capacity and a higher risk of
developing systemic thromboembolic events and of dying than
those with sinus rhythm (SR). However, these findings have
not been confirmed by other studies (7–11). The heteroge-
neous patient groups investigated and the retrospective design
of some of these studies may account for the discrepancies.
Accordingly, a large group of patients with CHF and SR was
prospectively investigated to assess the incidence and the
predictors of AF. We also investigated whether this arrhyth-
mia, once developed, had any adverse consequences.
Methods
Study patients. The study included 354 patients with CHF
and SR consecutively admitted to our heart failure unit
between September 1992 and May 1995 for evaluation for
heart transplantation. All patients had experienced more than
two episodes of CHF requiring hospital admission in the 6
months preceding the admission to our center. After admis-
sion, therapy was optimized to achieve a stable clinical condi-
tion. Ten patients with refractory CHF requiring infusion of
inotropic or vasodilator medications, or both, were excluded
from the analysis, leaving a final study group of 344 patients
whose general characteristics are summarized in Table 1. All
patients received diuretic drugs with a flexible regimen and
high dose angiotensin-converting inhibitors, if tolerated. Dig-
italis was always administered if not contraindicated, and
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amiodarone was usually given in the case of previous sustained
atrial or ventricular arrhythmias.
Measurements. All investigations were performed after
the patient’s condition had been stabilized and therapy opti-
mized according to clinical criteria. Venous blood was col-
lected for routine measurements, including serum electrolytes
and thyroid hormones and, in a subgroup of 206 consecutive
patients, plasma norepinephrine was determined by high per-
formance liquid chromatography. The amplitude and the
duration of the P wave were recorded from a standard 12 lead
surface electrocardiogram (ECG). Baroreflex sensitivity was
assessed by the phenylephrine test using a previously described
method (12).
Exercise capacity was assessed by a symptom-limited tread-
mill cardiopulmonary exercise test, and expiratory gases were
analyzed using a Medical Graph System 2001 analyzer. Peak
oxygen consumption was measured by averaging the value of
the final 30 s of exercise.
Right heart catheterization was performed using a 7F Swan
Ganz balloon-tipped catheter inserted into the right internal
jugular vein and advanced through the right heart cavities into
the pulmonary artery. Standard hemodynamic measurements
were obtained using a 7005 Marquette polygraph. Cardiac
output was measured by the thermodilution method.
Hewlett-Packard Sonos 1000 and 2500 systems with 2.5-
and 3.5-MHz probes were used to perform Doppler and
two-dimensional echocardiographic examinations. Left atrial
and left ventricular diameters were measured by M-mode
echocardiography according to the recommendations of the
American Society of Echocardiography (13). Right and left
atrial and left ventricular volumes were assessed by two-
dimensional apical two- and four-chamber views using the
modified Simpson’s rule. Atrial emptying fractions were calcu-
lated according to the formula: Maximal volume 2 Minimal
volume/Maximal volume p 100. Mitral and tricuspid regurgita-
tions were diagnosed by color Doppler and quantified using a
41 grading system (14). Mitral diastolic flow velocity was
assessed by pulsed Doppler from the apical four-chamber view
by positioning the sample volume between the leaflets at the
level of their tips in diastole. The following measurements were
averaged from five consecutive cycles: maximal early diastolic
velocity, maximal late diastolic velocity, their ratio and the
deceleration time of early diastolic velocity. When patients
were in AF the measurements obtained in 10 cycles were
analyzed.
Follow-up. Patients underwent serial clinical, laboratory,
ergometric, hemodynamic and echocardiographic evaluations
every 6 months. Between these intervals, telephone contact
with the patients, next of kin, referral physicians and peripheral
hospitals were used at intervals of 3 months to verify patient
status. No patient was lost to follow-up.
The development of chronic AF was the primary end point
in this study. When AF occurred, patients were admitted to the
hospital, potential precipitating factors were searched for and
treated; medical therapy was optimized to stabilize hemody-
namic conditions and to control ventricular heart rate. Oral
anticoagulant agents were given to all patients with AF, and
the dose was adjusted to keep the international normalized
ratio (INR) between 2 and 3. A low dose regimen of amioda-
rone was also started. About 4 weeks after anticoagulation, if
the arrhythmia did not subside, transthoracic synchronized
direct current cardioversion was attempted when not contra-
indicated (15). Left atrial dilation was not considered as an
absolute contraindication. Patients in whom SR could not be
restored, and AF was present at hospital discharge, and those
in whom the arrhythmia recurred after an initially successful
cardioversion, and its persistence was documented by serial
ECGs, were considered as having chronic AF (Fig. 1). Parox-
ysmal AF, defined according to the criteria proposed by Levy
et al. (16), and AF lasting .7 days and then successfully
cardioverted were defined as reversible AF and analyzed to-
gether.
Once chronic AF developed, all patients were given digi-
talis, and six patients also received low dose amiodarone in an
attempt to obtain adequate ventricular rate control. Then, to
assess whether AF was associated with any clinical or hemo-
dynamic deterioration, all patients underwent a complete
reevaluation 3 6 3 months after the onset of the arrhythmia.
The prognosis of patients who remained in SR and those
who developed chronic AF was assessed by considering as
major events cardiac death and urgent heart transplantation.
Systemic thromboembolisms were separately considered minor
events and classified as 1) ischemic strokes, defined as the
abrupt onset of focal neurologic deficit in the distribution
territory of a single brain artery persisting for .24 h and
confirmed by a computed tomographic or magnetic resonance
imaging scan; 2) transient ischemic attacks, defined as focal
Abbreviations and Acronyms
AF 5 atrial fibrillation
CHF 5 chronic congestive heart failure
ECG 5 electrocardiogram
INR 5 international normalized ratio
OR 5 odds ratio
SR 5 sinus rhythm
Table 1. Principal Characteristics of 344 Study Patients at Entry
Age (yr) 54 6 8
Men/women 303/41
NYHA functional class III/IV 166 (48%)
Peak VO2 (ml/kg per min) 14 6 5
Etiology of heart failure
Idiopathic 166 (48%)
Ischemic 146 (43%)
Valvular 17 (5%)
Other 15 (4%)
Pulmonary artery wedge pressure (mm Hg) 20 6 10
Cardiac index (liters/min per m2) 2.2 6 0.4
Left ventricular ejection fraction (%) 23 6 7
Data presented are mean value 6 SD or number (%) of patients.
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deficits lasting ,24 h; 3) peripheral embolization, defined as an
abrupt vascular insufficiency in any peripheral area associated
with evidence of arterial occlusion in the absence of other
likely mechanisms.
Statistical analysis. Results are given as mean value 6 SD.
The unpaired Student test and a Fisher exact test were used to
compare differences of continuous and categoric variables,
respectively, in patients with and without AF. Variables for
which a significant difference was observed between the two
groups were used as candidate predictors of AF in a multivar-
iate logistic regression model. Model identification was per-
formed according to a stepwise procedure using a p value of
0.05 as the threshold for entrance to or removal from the
model.
To be confident that the observed changes of clinical and
instrumental variables over time were not affected by different
baseline conditions, a statistically matched control group of
patients with stable SR was selected, as follows: a Gower’s
generalized distance from each of the patients who developed
AF during follow-up and all the patients who remained in SR
was computed and ranked in ascending order. The distance
was calculated using the following variables: age, New York
Heart Association functional class, exercise capacity, pulmo-
nary artery wedge pressure, cardiac index and mitral and
tricuspid regurgitations. The control group was then defined by
taking, for each patient who developed AF, the two closest
patients with SR who had had at least two serial evaluations.
Analysis of variance was then used to compare changes in the
variables tested between the two groups and was assessed by
testing for the interaction between the factor time and the
factor group.
To verify whether the development of AF had an adverse
prognostic effect (cardiac death and urgent heart transplanta-
tion), logistic regression analysis was performed. Because the
time to the onset of AF may vary widely among subjects,
exerting a confounding effect on the prognostic value of AF,
we attempted to minimize the effect of time by categorizing the
follow-up time into five periods lasting 300 days.
All statistical analyses were carried out using the SAS/
STAT statistical package, revision 6.10 (17). A p value , 0.05
was considered statistically significant.
Results
Development of AF. During a follow-up period of 19 6 12
months, AF developed in 28 patients. AF persisted despite
cardioversion in 9 patients, whereas SR was restored by
pharmacologic (9) or electrical cardioversion (10) in 19. In 10
of these 19 patients, SR persisted throughout follow-up,
whereas AF reoccurred in 9, and SR could not be restored.
Thus, 18 patients (5%) overall developed chronic AF (Fig. 1).
At baseline, patients who developed chronic AF did not
differ from those who remained in SR for any variable tested.
This result was valid both for all patients enrolled in the study
and for the subgroup of patients who survived free of heart
transplantation at least 6 months (who therefore had had at
least two evaluations in SR) (Table 2, left-hand columns).
When the variables measured in the two groups at the last
evaluation (for patients who developed AF we considered the
last evaluation in SR, obtained 3 6 3 months before the onset
of the arrhythmia) were considered, maximal late diastolic
velocity of mitral flow was significantly lower in patients who
subsequently experienced AF than in patients with stable SR,
whereas maximal early diastolic velocity was higher in the
former than in the latter. Left atrial emptying fraction was also
more compromized in patients with subsequent AF. No differ-
ences were found in hemodynamic variables, and within the
clinical variables, only previous reversible AF was significantly
(p 5 0.0001) associated with late development of chronic AF
(Table 2, right-hand columns). Regression logistic analysis
retained previously reversible AF (Wald chi-square 17.8, odds
ratio [OR] 55.2, p 5 0.0001) and reduced maximal late
diastolic mitral flow velocity (Wald chi-square 6.9, OR 1.3, p 5
0.005), measured during the last evaluation in SR, as indepen-
dent predictors of the onset of chronic AF. The sensitivity of
the model, using a threshold probability value of 0.5, for
predicting the onset of the arrhythmia was 99%, whereas the
specificity was only 19%.
When the 18 patients who developed chronic AF were
compared with the 10 patients in whom the AF reverted to SR,
the only significant difference found was in late diastolic mitral
flow velocity (25 6 14 vs. 48 6 24 cm/s, p 5 0.03), whereas
hemodynamic variables, atrial volumes and severity of atrio-
ventricular valve regurgitation did not predict the success of
the cardioversion.
Clinical and hemodynamic changes associated with onset
of AF. In eight patients the onset of AF was accompanied by
overt heart decompensation. In most cases the arrhythmia
occurred when patients were at home, so it was not possible to
establish with certainty whether its onset preceded or followed
heart decompensation. In the remaining 10 patients clinical
status was relatively stable. In all but four patients, who
Figure 1. Flowchart showing the occurrence of AF in 344 patients
(pts) with SR during follow-up. Twenty-eight patients (8%) developed
AF. AF persisted in 9 patients despite cardioversion, whereas SR was
restored in 19 patients. SR persisted in 10 of these 19 patients
throughout the follow-up, whereas AF occurred in the remaining 9,
and SR could not be restored. Thus, overall, 18 patients (5%)
developed chronic AF.
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remained in functional class IV, clinical conditions could be
stabilized by adjusting medical therapy, and in no patient did
the hemodynamic deterioration prompt urgent cardioversion.
However, even after therapy optimization, the functional class
deteriorated in 9 of 18 patients (Fig. 2). Concomitantly, peak
oxygen consumption, which had been stable during follow-up
when the patients were in SR, had decreased in the first
evaluation after development of AF from 16 6 5 to 11 6
5 ml/kg per min despite an increase in heart rate at peak
exercise (Table 3). Again in the first evaluation after the onset
of AF, cardiac index markedly decreased (Fig. 3), the severity
of tricuspid and mitral regurgitation increased, and both right
and left atrial volumes increased further (Fig. 4, Table 3). Left
ventricular dimensions and ejection fractions remained un-
changed. The matched patients who remained in stable SR did
Figure 2. Changes in New York Heart Association (NYHA) func-
tional class in the 18 patients who developed chronic AF before and
after the onset of AF.
Table 2. Characteristics of Patients With Sinus Rhythm Classified According to Development of Chronic Atrial Fibrillation During
Follow-Up*
Variable
Baseline Evaluation Last Evaluation in SR
Subsequent Chronic
AF (n 5 18)
Stable SR
(n 5 290) p Value
Subsequent Chronic
AF (n 5 18)
Stable SR
(n 5 290) p Value
Clinical
Age (yr) 54 6 10 54 6 8 NS
Men/women 14/4 255/35 NS
NYHA functional class 2.3 6 0.5 2.3 6 0.5 NS 2.4 6 0.5 2.6 6 0.6 NS
Serum sodium (mEq/liter) 137 6 4 138 6 3 NS 137 6 3 138 6 10 NS
Heart rate (beats/min) 72 6 16 76 6 14 NS 75 6 13 73 6 13 NS
Valvular etiology of heart failure 3 (12%) 13 (4%) NS
Ergometry
Maximal heart rate (beats/min) 131 6 18 126 6 21 NS 130 6 19 124 6 20 NS
Peak VO2 (ml/kg per min) 16 6 4 14 6 5 NS 16 6 5 15 6 5 NS
Neurohormonal pattern
Norepinephrine (pg/ml) 332 6 194 355 6 210 NS 340 6 154 379 6 224 NS
Thyrotropin (mU/liter) 1.6 6 0.9 2.3 6 2 NS 1.7 6 0.9 2.2 6 1.8 NS
Free thyroxine (ng/100 ml) 1.8 6 0.5 1.5 6 0.6 NS 1.9 6 0.5 1.5 6 0.6 NS
Free three iodothyronine (pg/ml) 7.3 6 4 7.3 6 5 NS 8.1 6 4 7.2 6 4 NS
Electrocardiography
Maximal P wave amplitude (mV) 0.16 6 0.06 0.19 6 0.08 NS 0.17 6 0.09 0.18 6 0.07 NS
Maximal P wave duration (ms) 96 6 40 138 6 55 NS 108 6 60 132 6 71 NS
Episodes of reversible AF during follow-up 9 (50%) 10 (3%) 0.0001
Baroreflex sensitivity (ms/mm Hg) 3.2 6 2 4.5 6 4 NS 3.0 6 2 5.0 6 4 NS
Hemodynamic pattern
Pulmonary artery wedge pressure (mm Hg) 23 6 9 19 6 10 NS 21 6 7 18 6 10 NS
Right atrial pressure (mm Hg) 7 6 5 5 6 4 NS 7 6 6 5.2 6 4 NS
Cardiac index (liter/min per m2) 2.1 6 0.4 2.2 6 0.5 NS 2.2 6 0.4 2.2 6 0.6 NS
Echocardiography
Left ventricular ejection fraction (%) 24 6 6 23 6 7 NS 25 6 7 24 6 7 NS
Left ventricular end-diastolic diameter (mm) 73 6 14 72 6 10 NS 74 6 14 72 6 10 NS
Maximal left atrial volume (ml) 78 6 22 82 6 50 NS 90 6 25 81 6 63 NS
Maximal right atrial volume (ml) 59 6 38 57 6 35 NS 66 6 37 55 6 34 NS
Left atrial emptying fraction (%) 26 6 10 31 6 16 NS 19 6 18 32 6 14 0.005
Right atrial empyting fraction (%) 23 6 14 32 6 14 NS 28 6 12 32 6 14 NS
Tricuspid regurgitation (4-grade score) 0.7 6 1 1 6 1 NS 1 6 1.2 1 6 1.1 NS
Mitral regurgitation (4-grade score) 1.4 6 1 1.8 6 1.2 NS 1.8 6 1.1 1.9 6 1.2 NS
Maximal early diastolic mitral flow velocity (cm/s) 73 6 26 74 6 26 NS 95 6 19 73 6 26 0.02
Maximal late diastolic mitral flow velocity (cm/s) 37 6 12 42 6 23 NS 25 6 14 45 6 25 0.04
Early diastolic deceleration time of transmitral flow (ms) 118 6 32 132 6 54 NS 121 6 32 151 6 64 NS
*Only patients with at least two evaluations in SR were considered. Data presented are mean value 6 SD or number (%) of patients. AF 5 atrial fibrillation; SR 5
sinus rhythm; other abbreviations as in Table 1.
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not show significant changes in most of the variables tested,
and only functional class and mitral and tricuspid regurgitation
significantly worsened (Table 3). Table 4 shows the significance
of differences in variations during follow-up of measurements
obtained in patients who developed AF (before and after the
event) and in those who remained in SR.
Prognostic significance of development of chronic AF.
Despite anticoagulation, 3 of 18 patients experienced a stroke,
which was fatal in 2. At the time of the events the INR was 1.5,
2.0 and 2.6, respectively. Systemic thromboembolism (two
strokes and two peripheral emboli) occurred in only 4 (1.2%)
of the 326 patients with SR, 128 of whom (39%) received
anticoagulation. Major cardiac events (27 sudden deaths, 61
pump failure deaths, 26 urgent heart transplantations) oc-
curred in 114 (33%) of the 344 patients. Of the 18 patients who
developed chronic AF, 9 had a major event (50%). When the
first 300 days from the onset were considered, AF was signif-
icantly associated (p 5 0.02, OR 4) with cardiac events,
whereas it had no influence on patients who survived longer
than that period.
Discussion
It is commonly believed that AF exerts a negative hemody-
namic effect because of the loss of atrial transport and impair-
ment of ventricular rate control, reduces exercise performance,
predisposes to systemic thromboembolism and triggers left
ventricular arrhythmias. It has seemed reasonable to postulate
that these unfavorable effects may become particularly delete-
rious in patients with CHF and a limited cardiac reserve, an
impaired exercise tolerance and higher risk of thromboembo-
Table 3. Changes in Clinical, Hemodynamic and Echocardiographic Variables Observed in 18 Patients Who Developed Chronic Atrial
Fibrillation During Follow-Up and in 36 Matched Patients With Sinus Rhythm
Variable
AF Group (mean 6 SD) (n 5 18)
Control Group (mean 6 SD) (n 5 36)
Baseline
Last
Evaluation
in SR
Final
Evaluation
in AF p Value Baseline
Last
Evaluation p Value
Clinical
NYHA functional class 2.3 6 0.5 2.4 6 0.5 2.9 6 0.6* 0.0001 2.2 6 0.4 2.6 6 0.5 0.0001
Heart rate (beats/min) 72 6 16 75 6 13 78 6 10 NS 84 6 15 82 6 14 NS
Maximal heart rate exercise (beats/min) 131 6 18 130 6 19 140 6 24* 0.03 127 6 9 124 6 6 NS
Peak VO2 (ml/kg per min) 16 6 4 16 6 5 11 6 5* 0.002 14 6 4 14 6 5 NS
Hemodynamic pattern
Systolic blood pressure (mm Hg) 107 6 6 106 6 7 104 6 6 NS 108 6 7 107 6 6 NS
Pulmonary artery wedge pressure (mm Hg) 23 6 9 21 6 7 24 6 7 NS 19 6 8 18 6 7 NS
Right atrial pressure (mm Hg) 7 6 5 7 6 6 9 6 6 NS 5 6 3 5 6 4 NS
Cardiac index (liter/min per m2) 2.1 6 0.4 2.2 6 0.4 1.8 6 0.4* 0.0008 2.4 6 0.4 2.2 6 0.5 NS
Echocardiography
Left ventricular ejection fraction (%) 24 6 6 25 6 7 25 6 6 NS 22 6 5 23 6 7 NS
Left ventricular end-diastolic diameter (mm) 73 6 14 72 6 10 74 6 15 NS 74 6 12 73 6 11 NS
Maximal left atrial volume (ml) 78 6 22 90 6 25† 114 6 33* 0.0001 61 6 26 69 6 27 NS
Maximal right atrial volume (ml) 59 6 38 66 6 37 82 6 34* 0.0001 46 6 21 50 6 23 NS
Left atrial emptying fraction (%) 26 6 10 19 6 18 NS 36 6 18 34 6 15 NS
Right atrial emptying fraction (%) 23 6 14 28 6 12 NS 33 6 14 36 6 13 NS
Tricuspid regurgitation (4-grade score) 0.7 6 1 1 6 1.2 1.8 6 1.2* 0.001 0.7 6 1 0.9 6 1 0.02
Mitral regurgitation (4-grade score) 1.4 6 1 1.8 6 1.1 2.4 6 1.4* 0.0001 1.4 6 1 1.6 6 1 0.03
Maximal early diastolic mitral flow velocity (cm/s) 73 6 26 95 6 19† 0.006 72 6 21 73 6 23 NS
Maximal late diastolic mitral flow velocity (cm/s) 37 6 12 25 6 14† 0.0001 42 6 22 48 6 23 NS
Early diastolic deceleration time of transmitral flow (ms) 118 6 32 121 6 33 NS 126 6 44 137 6 59 NS
Statistically significant by pairwise comparison: *last evaluation in sinus rhythm versus final evaluation in atrial fibrillation; †baseline versus last evaluation in sinus
rhythm. Abbreviations as in Tables 1 and 2.
Figure 3. Changes in cardiac index over time in patients who later
developed chronic AF (circles) versus those who remained in SR
(squares).
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lism and ventricular arrhythmias. Paradoxically, the belief that
AF adversely influences morbidity and mortality in these
patients has been recently challenged (8–11).
However, all previous studies investigated patients with AF
already present versus those with SR, which raises concerns
regarding the likelihood of selection bias. In fact, the most
compromized patients (who may not have survived long after
the onset of the arrhythmia) were likely to have been excluded,
whereas patients in whom AF was the cause of the occurrence
of CHF (a relatively benign condition reversible after slowing
heart rate) were likely to have been included. This selection
may limit the practical value of the results of these studies in
patients with CHF who develop primary AF.
In the present study we prospectively investigated a large
group of patients with CHF and SR. Our results show that in
these patients, the occurrence of AF cannot be predicted by
any baseline variable, whereas previous episodes of reversible
AF, reduced left atrial contribution to filling and reduced atrial
emptying fraction, observed during follow-up, were signifi-
cantly associated with a later occurrence of AF. Furthermore,
our study demonstrates that the occurrence of AF is associated
with clinical and hemodynamic deterioration and may predis-
pose to systemic thromboembolism.
Predictors of chronic AF. Several mechanisms, all of which
may potentially operate in CHF, may facilitate the onset and
maintenance of AF. Increased left atrial size and pressure are
generally believed to be important in the genesis of AF and are
regarded as causes of unsuccessful cardioversion and late
recurrence of the arrhythmia (18–22). In our study many
patients remained in stable SR despite markedly dilated atria
and elevated pressures. Furthermore, no differences were
found in atrial volumes or in right atrial and pulmonary artery
wedge pressures between patients who subsequently did or did
not develop AF. Perhaps the slow progression of the disease
allows a certain adaptation that minimizes the electrophysi-
ologic effects of atrial wall distension and could explain the
preservation of SR in many patients with CHF. This adapta-
tion may also account for the surprising finding that left atrial
dimensions were not predictive of conversion of AF to SR.
Autonomic tone and thyroid dysfunction may also play a
relevant role in the genesis of AF (23,24). Serum norepineph-
rine and baroreflex sensitivity greatly varied among patients
and were not predictive of the onset of AF. Moreover, in the
present study all patients who had AF were euthyroid.
In our experience, the only variables associated with later
onset of AF were the occurrence of reversible AF and the
reduction of the left atrial contribution to filling. The latter is
a new finding. Two factors may lead to the reduction of the left
atrial contribution to filling: an increase in left atrial afterload
because of a stiff left ventricle or, alternatively, a deterioration
of left atrial pump function (25,26). The finding that pulmo-
nary artery wedge pressure and the early diastolic deceleration
time of mitral flow (an indicator of left ventricular stiffness) did
not change points to the second mechanism and suggests that
in CHF the onset of AF is preceded by left atrial mechanical
dysfunction. An “atrial myopathy,” not entirely dependent on
mechanical overload, has been previously described in various
Figure 4. Changes in right and left atrial
maximal volumes over time in patients
who developed AF versus those who re-
mained in SR.
Table 4. Significance of Differences in Variables During Follow-Up
in Measurements Obtained in Patients with Atrial Fibrillation
(before and after the event) and in Those Remaining in
Sinus Rhythm
F Value p Value
NYHA functional class 5.3 NS
Peak VO2 (ml/kg per min) 16.8 0.0001
Pulmonary artery wedge pressure (mm Hg) 5 NS
Cardiac index (liters/min per m2) 8.9 0.003
Maximal left atrial volume (ml) 9.1 0.003
Maximal right atrial volume (ml) 13.6 0.0003
Tricuspid regurgitation (4-grade score) 7.4 0.002
Mitral regurgitation (4-grade score) 15.9 0.0001
Abbreviations as in Table 1.
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types of cardiomyopathies (27–29), and ischemia and fibrosis
of atrial myocardium may well occur in patients with ischemic
cardiomyopathy. However, the relation of such dysfunction to
later development of AF has not yet been described.
Clinical and hemodynamic changes associated with AF.
Despite an already impaired atrial transport, the development
of AF was associated with relevant clinical and hemodynamic
deterioration. The finding that the deterioration did not occur
from baseline to the last evaluation in SR, whereas it was
observed after the onset of AF, suggests that AF may play a
pathogenetic role in its determination. However, because of
the relatively long interval between the last evaluation in SR
and the onset of AF, it cannot be proved whether AF is the
cause or simply a marker of such deterioration. We can never
know the answer to this “chicken or the egg” question because
the pre-AF evaluation can inevitably only be performed at
some point before the onset of AF. However, arguments can
be made for a causal association by comparison of our data
with those obtained in previous studies.
The association between AF and exercise performance has
been extensively investigated, yielding discordant results
(4,7,30–32). Some studies that compared patients with CHF
with and without AF failed to demonstrate any significant
difference in exercise tolerance (7). In contrast, other studies
investigating patients before and after cardioversion found an
improvement (4,30). Our findings are in line with those
observed after cardioversion and show that the development of
AF from SR is associated with a reduction in exercise tolerance
despite the higher exercise heart rates that were reached. Lack
of hemodynamic monitoring during exercise limits the inter-
pretation of these results. It can be hypothesized that impaired
ventricular filling or an increase in mitral and tricuspid regur-
gitation may have reduced cardiac index during exercise.
At rest, cardiac index was indeed much lower after the
onset of AF. The importance of atrial contribution to filling in
the maintenance of cardiac output was recognized several
decades ago (33). However, in patients with severe CHF and
elevated left ventricular filling pressures, left atrial transport is
considered less important (26). Confirming this observation we
found that left ventricular filling at atrial contraction was
impaired in many patients, particularly in those who later
developed AF. Yet, after loss of atrial transport because of AF,
cardiac index decreased by ;20%. Loss of right atrial transport
(not assessed in the present study), the ineffectiveness of the
ventricles to generate significant outflow because of a too short
ECG RR interval and worsening in mitral and tricuspid
regurgitation may explain this finding.
Vigorous, synchronized atrial contraction has long been
recognized as an important factor in determining the closure of
mitral and tricuspid valves and in preventing regurgitation
(34–36). The absence of these contractions may be particularly
deleterious in patients with dilated ventricles and may offer a
plausible explanation for the increased severity of mitral and
tricuspid regurgitation observed after the onset of AF.
Another potentially adverse effect of AF was the marked
increase in left and right atrial volumes. There has been
intense debate on the cause/effect relation between AF and
atrial enlargement (18,37,38). It was recently shown (38) that
in patients with normal left ventricular function, atrial enlarge-
ment follows the onset of AF. Concordantly, in our study atrial
dimensions increased in the evaluation after the onset of AF,
however, atrial volumes were much greater, and their increase
was documented sooner after the development of the arrhyth-
mia. The effects of AF, combined with those of elevated atrial
pressures and valvular regurgitations, may have further con-
tributed to atrial dilation in our patients with CHF. Whatever
the mechanism, left atrial enlargement may predispose to
systemic thromboembolism (39). Indeed 3 of the 18 patients
who developed chronic AF had a stroke within a few months.
This finding confirms the results of one of our previous studies,
which showed that in patients with chronic CHF, AF associ-
ated with low cardiac output is a strong predictor of thrombo-
embolic risk (40). However, other reports failed to demon-
strate this association, probably because of increased use of
anticoagulant agents in patients with a presumed higher risk
(i.e., those with AF) (8,10). There is similar uncertainty
concerning the relation of AF to mortality in patients with
CHF (6,9,11,41). In our study, in which the impact of AF could
be assessed from its onset (albeit in a limited cohort), major
cardiac events occurred relatively soon after the onset of AF in
half of the patients.
Limitations and conclusions. Some limitations of the study
must be acknowledged: 1) The study was carried out in a
referral center recruiting patients from all of Italy. For this
reason, the frequency of serial evaluations established by the
protocol was kept to a minimum, so that the time interval
between the last evaluation in SR and the event was variable
and, in some patients, rather long. 2) Although patients were
carefully followed up, it cannot be ruled out that some of those
who were classified as having stable SR had episodes of
undocumented AF, and conversely those classified with
chronic AF may have had intermittent phases of SR. 3) The
number of patients who developed AF was too small to draw
firm conclusions regarding the prognostic significance of AF.
Despite these limitations the present study shows that in
patients with CHF and SR, the development of AF is not
infrequent. Its prediction, despite the large set of variables
considered, remains elusive. Only previous episodes of revers-
ible AF and an impaired left atrial contribution to filling
observed during follow-up were associated with an increased
risk of developing chronic AF, but the low specificity of the
model obtained limits the practical value of these findings.
Perhaps, we can speculate that patients with reversible AF
should be medically treated (with amiodarone or beta-
adrenergic blocking agents), and those with a progressive
decrease in atrial transport should be unloaded by a more
aggressive vasodilator in an attempt to maximize preservation
of atrial function and prevent chronic AF. Primary AF is
associated with relevant clinical and hemodynamic deteriora-
tion, predisposes to thromboembolism and is linked to a poor
prognosis. If AF is at least in part a cause of the deterioration,
more aggressive attempts to prevent and cardiovert AF might
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improve prognosis. However, further studies aimed directly at
this point are needed.
We thank Rachel Stenner, MBBS, for help in the preparation of the manuscript.
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